[go: up one dir, main page]

RU2008106445A - Вирусоподобные корпускулы (частицы) в качестве противопарамиксовирусной вакцины - Google Patents

Вирусоподобные корпускулы (частицы) в качестве противопарамиксовирусной вакцины Download PDF

Info

Publication number
RU2008106445A
RU2008106445A RU2008106445/13A RU2008106445A RU2008106445A RU 2008106445 A RU2008106445 A RU 2008106445A RU 2008106445/13 A RU2008106445/13 A RU 2008106445/13A RU 2008106445 A RU2008106445 A RU 2008106445A RU 2008106445 A RU2008106445 A RU 2008106445A
Authority
RU
Russia
Prior art keywords
particles
virus
corpuscles
newcastle disease
cell
Prior art date
Application number
RU2008106445/13A
Other languages
English (en)
Inventor
Труди Дж. МОРРИСОН (US)
Труди Дж. МОРРИСОН
Гомер Д. ПАНТУА (US)
Гомер Д. ПАНТУА
Original Assignee
Юниверсити Оф Массачусетс Медикал Скул (Us)
Юниверсити Оф Массачусетс Медикал Скул
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юниверсити Оф Массачусетс Медикал Скул (Us), Юниверсити Оф Массачусетс Медикал Скул filed Critical Юниверсити Оф Массачусетс Медикал Скул (Us)
Publication of RU2008106445A publication Critical patent/RU2008106445A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18423—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18523—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18623—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

1. Способ, включающий: ! а) обеспечение ! I. экспрессирующего вектора, включающего последовательности ДНК, кодирующие матричный белок вируса ньюкаслской болезни; ! II. клетки, которые могут быть трансфецированы («transfected») вышеописанным вектором; ! б) трансфекцию (transfecting) вышеописанной клетки указанным вектором в условиях, при которых генерируются частицы (корпускулы), подобные вирусу ньюкасльской болезни. ! 2. Способ по п.1, дополнительно включающий операцию: ! с) сбор указанных вирусоподобных частиц (корпускул) для создания бесклеточного препарата, содержащего частицы. ! 3. Способ по п.2, дополнительно включающий операцию: ! d) введение вакцины, содержащей указанный препарат, курице. ! 4. Способ по п.2, где указанная клетка является частью клеточной культуры и указанный сбор клеток, выросших в культуре, включает в себя получение указанных частиц (корпускул) из супернатанта (надосадочной жидкости) указанной культуры. ! 5. Способ по п.4, где вышеописанная клеточная культура содержит птичьи клетки. ! 6. Способ по п.1, где указанный вектор дополнительно включает последовательности ДНК кодирующие дополнительные вирусные протеины ньюкаслской болезни, выбранные из группы, состоящей из протеинов-нуклеокапсидов, химерного белка (a fusion protein) и геммаглютинина-нейраминидазы (hemagglutinin-neuraminidse protein). ! 7. Способ по п.1, где указанные корпускулы свободны от вирусных ДНК ньюкаслской болезни. ! 8. Трансфецированная (transfected) клетка по п.1. ! 9. Приготовление частиц (корпускул), созданных согласно п.2. ! 10. Способ, включающий следующие операции: ! a) Обеспечение ! I. вакцины, содержащей вирусоподобные частицы (корпускулы, virus-like particles), подобные вирусу ньюкаслской бол

Claims (15)

1. Способ, включающий:
а) обеспечение
I. экспрессирующего вектора, включающего последовательности ДНК, кодирующие матричный белок вируса ньюкаслской болезни;
II. клетки, которые могут быть трансфецированы («transfected») вышеописанным вектором;
б) трансфекцию (transfecting) вышеописанной клетки указанным вектором в условиях, при которых генерируются частицы (корпускулы), подобные вирусу ньюкасльской болезни.
2. Способ по п.1, дополнительно включающий операцию:
с) сбор указанных вирусоподобных частиц (корпускул) для создания бесклеточного препарата, содержащего частицы.
3. Способ по п.2, дополнительно включающий операцию:
d) введение вакцины, содержащей указанный препарат, курице.
4. Способ по п.2, где указанная клетка является частью клеточной культуры и указанный сбор клеток, выросших в культуре, включает в себя получение указанных частиц (корпускул) из супернатанта (надосадочной жидкости) указанной культуры.
5. Способ по п.4, где вышеописанная клеточная культура содержит птичьи клетки.
6. Способ по п.1, где указанный вектор дополнительно включает последовательности ДНК кодирующие дополнительные вирусные протеины ньюкаслской болезни, выбранные из группы, состоящей из протеинов-нуклеокапсидов, химерного белка (a fusion protein) и геммаглютинина-нейраминидазы (hemagglutinin-neuraminidse protein).
7. Способ по п.1, где указанные корпускулы свободны от вирусных ДНК ньюкаслской болезни.
8. Трансфецированная (transfected) клетка по п.1.
9. Приготовление частиц (корпускул), созданных согласно п.2.
10. Способ, включающий следующие операции:
a) Обеспечение
I. вакцины, содержащей вирусоподобные частицы (корпускулы, virus-like particles), подобные вирусу ньюкаслской болезни, указанные частицы, содержат матричные протеины вируса ньюкаслской болезни;
II. реципиента, восприимчивого к ньюкаслской болезни;
b) иммунизацию указанного реципиента указанной вакциной при условиях образования антител к вирусоподобным частицам (корпускулам).
11. Способ по п.10, где указанный реципиент выбран из группы, представленной птичьими, мышиными и человеческими клетками.
12. Способ по п.10, где указанные корпускулы далее включают в себя один или более добавочных вирусных протеинов ньюкаслской болезни, выбранных из группы, состоящей из протеинов-нуклеокапсидов, химерного белка и геммаглютинина-нейраминидазы.
13. Вакцина содержащая корпускулы, подобные вирусу ньюкаслской болезни; указанные корпускулы включают в себя матричные протеины вируса ньюкаслской болезни.
14. Вакцина по п.13, где вышеописанные корпускулы свободны от вирусной ДНК ньюкаслской болезни.
15. Вакцина по п.13, где указанные корпускулы дополнительно включают один или более добавочных вирусных протеинов, выбранных из группы, состоящей из протеина-нуклеокапсида, химерного белка и геммаглютинина-нейраминидазы.
RU2008106445/13A 2005-08-05 2006-08-03 Вирусоподобные корпускулы (частицы) в качестве противопарамиксовирусной вакцины RU2008106445A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US70612605P 2005-08-05 2005-08-05
US60/706,126 2005-08-05
US11/497,888 US7951384B2 (en) 2005-08-05 2006-08-02 Virus-like particles as vaccines for paramyxovirus
US11/497,888 2006-08-02

Publications (1)

Publication Number Publication Date
RU2008106445A true RU2008106445A (ru) 2009-09-10

Family

ID=37727898

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008106445/13A RU2008106445A (ru) 2005-08-05 2006-08-03 Вирусоподобные корпускулы (частицы) в качестве противопарамиксовирусной вакцины

Country Status (13)

Country Link
US (2) US7951384B2 (ru)
EP (1) EP1917033B1 (ru)
JP (2) JP5342234B2 (ru)
KR (1) KR101120784B1 (ru)
CN (1) CN101282744B (ru)
AT (1) ATE528016T1 (ru)
AU (1) AU2006278588A1 (ru)
BR (1) BRPI0614702A2 (ru)
CA (1) CA2617508C (ru)
IL (1) IL189313A (ru)
NZ (1) NZ565961A (ru)
RU (1) RU2008106445A (ru)
WO (1) WO2007019247A2 (ru)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH668505A5 (de) 1985-03-20 1988-12-30 Bbc Brown Boveri & Cie Halbleiterbauelement.
MX2008000850A (es) 2005-07-29 2008-03-18 Solvay Pharm Gmbh Procedimientos para la fabricacion de polvo de pancreatina esterilizada.
US9216212B2 (en) 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
US20080233150A1 (en) * 2006-11-16 2008-09-25 Gale Smith Respiratory syncytial virus-virus like particle (vlps)
US20100247574A1 (en) * 2007-02-21 2010-09-30 Kutub Mahmood CHIMERIC NEWCASTLE DISEASE VIRUS VLPs
WO2009012487A2 (en) * 2007-07-19 2009-01-22 Novavax, Inc. Chimeric varicella zoster virus-virus like particles
WO2009055491A2 (en) * 2007-10-22 2009-04-30 University Of Rochester Respiratory syncytial virus vaccine based on chimeric papillomavirus virus-like particles or capsomeres
US20110014231A1 (en) * 2007-11-05 2011-01-20 Mor Research Applications Ltd Anti-measles cancer immunotherapy
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
WO2009132195A1 (en) * 2008-04-23 2009-10-29 Michigan State University Immortal avian cell line and methods of use
JP2010122205A (ja) * 2008-08-29 2010-06-03 Sysmex Corp 麻疹ウイルス検出方法、メンブレンアッセイ用試験具およびメンブレンアッセイ用試験キット
WO2010039224A2 (en) 2008-09-30 2010-04-08 University Of Massachusetts Medical School Respiratory syncytial virus (rsv) sequences for protein expression and vaccines
PL3067064T3 (pl) * 2008-12-09 2020-11-02 Novavax, Inc. Zmodyfikowane białka f rsv i sposoby ich wykorzystania
EP2413962A1 (en) 2009-03-30 2012-02-08 Mount Sinai School of Medicine Influenza virus vaccines and uses thereof
JP5797636B2 (ja) * 2009-04-03 2015-10-21 メリアル リミテッド ニューカッスル病ウイルスをベクターとするトリワクチン
SI3178490T1 (sl) * 2009-07-15 2022-08-31 Glaxosmithkline Biologicals S.A. Sestavki proteina F RSV-ja in postopki za pripravo le-teh
CN103977394B (zh) * 2009-07-17 2016-03-09 翰林大学校产学协力团 包含脂质体包胶的寡核苷酸和表位的免疫刺激性组合物
US20110097358A1 (en) * 2009-10-12 2011-04-28 Techno Vax, Inc. RESPIRATORY SYNCYTIAL VIRUS (RSV) VIRUS-LIKE PARTICLES (VLPs)
WO2011090708A2 (en) * 2009-12-28 2011-07-28 Merial Limited Recombinant ndv antigen and uses thereof
MX2012011300A (es) 2010-03-30 2012-11-29 Sinai School Medicine Vacunas del virus de influenza y usos de las mismas.
BR112013000244A2 (pt) 2010-07-06 2016-05-17 Novartis Ag lipossomas com lipídeos apresentando pka vantajoso para administração de rna
DK3243526T3 (da) 2010-07-06 2020-02-17 Glaxosmithkline Biologicals Sa Levering af rna til at udløse flere immunsignalveje
EP2591114B1 (en) 2010-07-06 2016-06-08 GlaxoSmithKline Biologicals SA Immunisation of large mammals with low doses of rna
RS63315B1 (sr) 2010-08-31 2022-07-29 Glaxosmithkline Biologicals Sa Pegilovani lipozomi za isporuku rnk koja kodira imunogen
CA2814386C (en) * 2010-10-11 2019-08-20 Novartis Ag Antigen delivery platforms
CA2840989A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
IN2014CN02114A (ru) 2011-09-20 2015-05-29 Sinai School Medicine
KR101374192B1 (ko) * 2011-12-21 2014-03-14 대한민국 제4형 조류파라믹소바이러스 ｈｎ 단백질 및 이를 포함하는 ｈｉ법 검사용 항원진단액
IN2012DE00411A (ru) * 2012-02-14 2015-06-05 Council Scient Ind Res
CN102618668B (zh) * 2012-03-27 2013-08-28 广西壮族自治区兽医研究所 鸭新城疫病毒和鸭圆环病毒二重pcr检测试剂盒
EP4154907A1 (en) 2012-12-18 2023-03-29 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
AU2014239583B2 (en) 2013-03-14 2020-07-02 Children's Healthcare Of Atlanta, Inc. Recombinant RSV with silent mutations, vaccines, and methods related thereto
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
KR101546064B1 (ko) 2013-07-29 2015-08-20 건국대학교 산학협력단 인플루엔자 바이러스 매트릭스 1 단백질과 뉴캣슬 병 바이러스 융합 단백질을 발현하는 뉴캣슬 병 바이러스 바이러스 유사입자
CN104721817B (zh) * 2013-12-19 2018-04-17 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
CN103805600A (zh) * 2014-03-06 2014-05-21 福州大学 一种dna分子克隆方法
JP2018504412A (ja) 2015-01-23 2018-02-15 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン接種レジメン
US10314906B2 (en) 2015-03-18 2019-06-11 University Of Massachusetts Virus-like particle compositions and vaccines against Epstein-Barr virus infection and disease
US10426829B2 (en) 2015-09-03 2019-10-01 Novavax, Inc. Vaccine compositions having improved stability and immunogenicity
WO2017075125A1 (en) 2015-10-29 2017-05-04 Emory University Chimeric RSV, Immunogenic Compositions, and Methods of Use
WO2017087550A1 (en) * 2015-11-16 2017-05-26 Georgia State University Research Foundation, Inc. Tunable vaccine platform against pathogens of the paramyxovirus family
CA3040071A1 (en) * 2015-12-17 2017-06-22 The Penn State Research Foundation Paramyxovirus virus-like particles as protein delivery vehicles
EP3246410A1 (en) * 2016-05-19 2017-11-22 Klinikum rechts der Isar der Technischen Universität München Vsv/ndv hybrid viruses for oncolytic therapy of cancer
EP3255056A1 (en) * 2016-06-06 2017-12-13 Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives Method for producing self-assemblying paramyxoviral nucleocapsid-like particles and their uses
WO2017218624A1 (en) 2016-06-15 2017-12-21 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
EP3518967A4 (en) 2016-10-03 2020-04-29 University of Massachusetts Methods for immunizing pre-immune subjects against respiratory syncytial virus (rsv)
CN106636015B (zh) * 2016-12-20 2019-12-10 吉林大学 一种嵌合型新城疫病毒样颗粒的制备方法
US20200030432A1 (en) * 2017-03-17 2020-01-30 Modernatx, Inc. Zoonotic disease rna vaccines
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
CN112638411B (zh) * 2018-05-04 2025-03-04 斯拜生物技术有限公司 疫苗组合物
EP3810634A4 (en) 2018-06-21 2022-07-27 Icahn School of Medicine at Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
IL280880B2 (en) 2018-08-27 2025-04-01 Regeneron Pharma Using Raman Spectroscopy in Downstream Purification
WO2020068540A1 (en) 2018-09-24 2020-04-02 University Of Massachusetts Compositions and methods for making and using virus-like particles (vlps)
US11390853B2 (en) 2019-04-26 2022-07-19 Case Western Reserve University Freeze dried viral nanoparticle constructs
CN110628724B (zh) * 2019-09-25 2023-04-14 兰州生物制品研究所有限责任公司 一种三型副流感病毒野毒株及其应用
CN112500494B (zh) * 2020-11-09 2023-01-24 昆明市妇幼保健院 用于新型冠状病毒检测的抗原及其制备方法
AU2022208435A1 (en) 2021-01-18 2023-08-10 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof
CN113214366B (zh) * 2021-05-25 2023-03-03 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 一种重组新城疫病毒基质蛋白及其应用
CN114574452B (zh) * 2021-12-29 2023-07-21 扬州大学 Hn基因易位构建重组新城疫疫苗候选株vii-hnf的方法及用途
CN116479175B (zh) * 2023-03-13 2024-10-18 广州国家实验室 用于检测人副流感病毒核酸的检测系统、试剂盒及方法

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2518755B1 (fr) 1981-12-23 1986-04-11 Pasteur Institut Sonde contenant un acide nucleique modifie et reconnaissable par des anticorps specifiques et utilisation de cette sonde pour detecter et caracteriser une sequence d'adn homologue
US6022958A (en) 1986-08-13 2000-02-08 Bayer Corporation cDNAs coding for members of the carcinoembryonic antigen family
US4774339A (en) 1987-08-10 1988-09-27 Molecular Probes, Inc. Chemically reactive dipyrrometheneboron difluoride dyes
US5631154A (en) 1988-06-10 1997-05-20 Therion Biologics, Incorporated Self assembled, defective, non-self-propagating lentivirus particles
US5250431A (en) 1988-06-13 1993-10-05 Dana-Farber Cancer Institute, Inc. Alteration of the interaction of a T-cell receptor with a proteintyrosine kinase
US5486599A (en) 1989-03-29 1996-01-23 The Board Of Trustees Of The Leland Stanford Junior University Construction and use of synthetic constructs encoding syndecan
US5690938A (en) 1989-07-07 1997-11-25 Oravax, Inc. Oral immunization with multiple particulate antigen delivery system
GB8923123D0 (en) 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
US5274113A (en) 1991-11-01 1993-12-28 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5433896A (en) 1994-05-20 1995-07-18 Molecular Probes, Inc. Dibenzopyrrometheneboron difluoride dyes
US5589372A (en) 1990-09-26 1996-12-31 E. R. Squibb & Sons, Inc. Squalene synthetase
US5248782A (en) 1990-12-18 1993-09-28 Molecular Probes, Inc. Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes
US5187288A (en) 1991-05-22 1993-02-16 Molecular Probes, Inc. Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis
US5344760A (en) 1991-06-03 1994-09-06 Ciba Corning Diagnostics Corp. Method of cancer detection
US5847096A (en) 1991-08-30 1998-12-08 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services DNA constructs encoding CD4 fusion proteins
JPH07507441A (ja) 1991-11-01 1995-08-24 ジヨスリン・ダイアビーテイス・センター １型真性糖尿病に関連する抗原
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
US5939283A (en) 1992-12-31 1999-08-17 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from dog dander and uses therefor
WO1994015635A1 (en) 1993-01-11 1994-07-21 Dana-Farber Cancer Institute Inducing cytotoxic t lymphocyte responses
DE4400659C2 (de) 1993-01-16 1995-07-27 Manfred Dr Schawaller Verfahren zur Gewinnung nativer Domänen viraler Membranproteine, deren Verwendung, insbesondere als Impfstoff gegen HIV, sowie diese nativen Domänen viraler Membranproteine selbst
US6991797B2 (en) 1993-07-02 2006-01-31 Statens Serum Institut M. tuberculosis antigens
AUPM368994A0 (en) 1994-02-04 1994-02-24 Saramane Pty Ltd Malaria merozoite antigen subunit vaccine
US5709995A (en) 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
FR2717498B1 (fr) 1994-03-18 1996-05-03 Commissariat Energie Atomique Transcrits du gène de CMH de classe I HLA-G et leurs applications.
US5851993A (en) 1994-06-13 1998-12-22 Biotie Therapies Ltd. Suppression of tumor cell growth by syndecan-1 ectodomain
US5583816A (en) 1994-06-29 1996-12-10 Sgs-Thomson Microelectronics, Inc. Long write test
US6291157B1 (en) 1998-02-23 2001-09-18 Connaught Laboratories Limited Antigenically-marked non-infectious retrovirus-like particles
US6080408A (en) 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
US6689367B1 (en) 1995-09-27 2004-02-10 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
US6713066B1 (en) 1996-07-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
US6913881B1 (en) 1996-01-24 2005-07-05 Third Wave Technologies, Inc. Methods and compositions for detecting target sequences
US6699476B1 (en) 1996-07-15 2004-03-02 Peter L. Collins Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
JP4021493B2 (ja) 1996-11-08 2007-12-12 ザ ガヴァメント オブ ザ ユナイテッド ステイツ オブ アメリカ、レプリゼンテッド バイ ザ セクレタリー、 デパートメント オブ ヘルス アンド ヒューマン サーヴィスィズ Ｃ型肝炎ウイルス様粒子の合成および精製
US5916879A (en) 1996-11-12 1999-06-29 St. Jude Children's Research Hospital DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof
ES2513043T3 (es) 1997-03-26 2014-10-24 Imperial Innovations Limited Proteína de fusión anticoagulante anclada a membrana de la célula
US7037510B2 (en) 1997-04-18 2006-05-02 Statens Serum Institut Hybrids of M. tuberculosis antigens
US7250171B1 (en) 1997-05-23 2007-07-31 United States Of America As Represented By The Dept. Of Health & Human Services Construction and use of recombinant parainfluenza viruses expressing a chimeric glycoprotein
PT1336621E (pt) 1997-08-05 2006-08-31 Stressgen Biotechnologies Corp Respostas imunitarias contra antigenios dos vph, suscitadas por composicoes que incorporam um antigenio de vph e uma proteina do stress ou um vector de expressao com aptidao para a expressao destas proteinas
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US7105488B1 (en) 1998-02-27 2006-09-12 The United States Of America As Represented By The Department Of Health And Human Services G protein-coupled receptor antagonists
EP0974660A1 (en) * 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle disease virus infectious clones, vaccines and diagnostic assays
US6248327B1 (en) 1998-09-11 2001-06-19 Vanderbilt University Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis
US6355786B1 (en) 1998-10-30 2002-03-12 Vanderbilt University Purified and isolated protein zero related (PZR) and therapeutic and screening methods using same
EP1980617A1 (en) 1998-12-31 2008-10-15 Novartis Vaccines and Diagnostics, Inc. Improved expression of HIV polypeptides and production of virus-like particles
DE19906096A1 (de) 1999-02-13 2000-08-17 Walter Sebald Protein mit einem Heparin-bindenden Epitop
US6566074B1 (en) 1999-03-15 2003-05-20 The General Hospital Corporation Methods of modulating cell attachment and migration
US20030224017A1 (en) 2002-03-06 2003-12-04 Samal Siba K. Recombinant Newcastle disease viruses useful as vaccines or vaccine vectors
US6710173B1 (en) 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US6306628B1 (en) 1999-08-25 2001-10-23 Ambergen, Incorporated Methods for the detection, analysis and isolation of Nascent proteins
US7119165B2 (en) 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
US20040105871A1 (en) 2000-03-02 2004-06-03 Robinson Harriet L. Compositions and methods for generating an immune response
EP1156111A1 (en) 2000-05-19 2001-11-21 Stichting Dienst Landbouwkundig Onderzoek Chimeric arterivirus-like particles
DE60136356D1 (de) 2000-06-12 2008-12-11 Univ Saskatchewan Chimäres GapC Protein aus Streptococcus und dessen Verwendung zur Impfung und Diagnostik
AUPQ841800A0 (en) 2000-06-28 2000-07-20 Biomolecular Research Institute Limited Truncated egf receptor
EP1310551A4 (en) 2000-08-08 2004-09-22 Kitasato Inst VIRAL-LIKE MICROGRAINS AND METHOD FOR THE PRODUCTION THEREOF
US6942866B2 (en) 2000-08-16 2005-09-13 Apovia, Inc. Malaria immunogen and vaccine
JP2002079971A (ja) * 2000-09-06 2002-03-19 Honda Motor Co Ltd 車両用ウインドシールド
CA2441952C (en) 2001-03-26 2010-06-01 Walter Reed Army Institute Of Research Plasmodium falciparum ama-1 protein and uses thereof
US7029685B2 (en) 2001-03-26 2006-04-18 The United States Of America As Represented By The Secretary Of The Army Plasmodium falciparum AMA-1 protein and uses thereof
AU2002258621A1 (en) 2001-03-28 2002-10-21 Children's Medical Center Corporation Fusion protein construct and method for inducing hiv-specific serum igg and secretory iga antibodies in-vivo
AR035867A1 (es) 2001-04-24 2004-07-21 Innogenetics Nv Una particula semejante a un virus hcv formada por una proteina de envoltura de hcv, un metodo para formar dicha particula, un medicamento que la contiene, una vacuna, un metodo de deteccion, un kit de diagnostico, el uso de cepas de hansenula o saccharomyces para la expresion de una proteina hcv, e
WO2002101072A2 (en) 2001-06-07 2002-12-19 Rigel Pharmaceuticals, Inc. Letm1: modulators of cellular proliferation
US6695545B2 (en) 2001-10-11 2004-02-24 Gregory M. Boston Soil stabilization composition
US7101566B2 (en) 2002-06-28 2006-09-05 Ethicon, Inc. Polymer coated microparticles for sustained release
ATE516045T1 (de) 2003-01-24 2011-07-15 Univ Massachusetts Medical Identifikation von vaccinia-virus-dominanten t- zell-epitopen
US20050002953A1 (en) 2003-05-06 2005-01-06 Jens Herold SARS-coronavirus virus-like particles and methods of use
JP2007502623A (ja) 2003-05-09 2007-02-15 リサーチ ディベロップメント ファウンデーション 膜タンパク質におけるフリンプロテアーゼ開裂部位の挿入およびその使用法
US7189403B2 (en) 2003-06-30 2007-03-13 Institut Pasteur Attenuated flavivirus strains containing a mutated M-ectodomain and their applications
EP1995256A1 (en) 2003-07-30 2008-11-26 University of Pittsburgh of the Commonwealth System of Higher Education EPHA2 T-cell epitope agonists and uses therefor
JP4647606B2 (ja) 2003-09-05 2011-03-09 ジェネンコー・インターナショナル・インク Ｈｐｖｃｄ８＋ｔ細胞エピトープ
US20100247574A1 (en) * 2007-02-21 2010-09-30 Kutub Mahmood CHIMERIC NEWCASTLE DISEASE VIRUS VLPs

Also Published As

Publication number Publication date
EP1917033A4 (en) 2009-09-02
IL189313A0 (en) 2008-06-05
JP5342234B2 (ja) 2013-11-13
KR20080072627A (ko) 2008-08-06
US20090068221A1 (en) 2009-03-12
US20070178120A1 (en) 2007-08-02
IL189313A (en) 2015-10-29
ATE528016T1 (de) 2011-10-15
EP1917033A2 (en) 2008-05-07
AU2006278588A1 (en) 2007-02-15
CN101282744A (zh) 2008-10-08
CA2617508A1 (en) 2007-02-15
BRPI0614702A2 (pt) 2011-04-12
EP1917033B1 (en) 2011-10-12
NZ565961A (en) 2011-11-25
WO2007019247A3 (en) 2008-01-17
KR101120784B1 (ko) 2012-04-20
US7951384B2 (en) 2011-05-31
JP2009502204A (ja) 2009-01-29
US9399059B2 (en) 2016-07-26
CN101282744B (zh) 2012-01-04
CA2617508C (en) 2013-12-31
WO2007019247A2 (en) 2007-02-15
JP2013176375A (ja) 2013-09-09
HK1125051A1 (en) 2009-07-31

Similar Documents

Publication Publication Date Title
RU2008106445A (ru) Вирусоподобные корпускулы (частицы) в качестве противопарамиксовирусной вакцины
Weaver et al. Chikungunya virus and prospects for a vaccine
ATE479742T1 (de) Verfahren zur grosstechnischen herstellung von impfstoffen
Marín-Lopez et al. Modeling arboviral infection in mice lacking the interferon alpha/beta receptor
Wang et al. A novel rabies vaccine expressing CXCL13 enhances humoral immunity by recruiting both T follicular helper and germinal center B cells
CN103122353A (zh) 一种猪o型口蹄疫病毒重组杆状病毒及制备方法和应用
WO2008034388A8 (en) Virus-like particles of capsid proteins from human papillomavirus type 16/58/18/6/11 and the method for preparation and the uses thereof
CN1065912C (zh) 用遗传工程方法生产减毒病毒
CN106867975A (zh) 新城疫病毒嵌合病毒样颗粒、疫苗及制备方法
CN102465144A (zh) 柯萨奇病毒a16型病毒样颗粒疫苗
CN102210861A (zh) 丙型肝炎病毒多表位肽负荷的树突状细胞治疗性疫苗
CN110981968A (zh) 含有狂犬病病毒g蛋白的融合蛋白及其制备方法、应用和疫苗
CN104531741B (zh) 增强hpv抗原表位肽免疫原性的方法及类病毒颗粒、颗粒制备方法与应用
CN105727280A (zh) 基于表达HBsAg的热失活全重组汉逊酵母细胞的乙肝治疗疫苗
Quadiri et al. The path towards effective long-lasting tissue-targeted prime/pull/keep herpes simplex therapeutic vaccines
CN103333916A (zh) 适应鸡新城疫病毒增殖的bhk细胞系的建立方法及其应用
CN109097341A (zh) 一种同时表达ha和hef的复制缺陷型重组流感病毒
CN101221176A (zh) 鸡γ-干扰素在重组杆状病毒中的表达及抗病毒活性的测定
CN103320451A (zh) 一种预防ev71基因工程蛋白质疫苗及其制备方法
CN108743934B (zh) 利用重组水泡性口炎病毒构建预防猪流行性腹泻病毒疫苗
Stobart et al. BAC-based recovery of recombinant respiratory syncytial virus (RSV)
CN103060276A (zh) 人二倍体细胞狂犬病疫苗病毒液制备方法
CN102234637B (zh) 重组甲型h1n1流感病毒灭活疫苗株(sc/pr8)的制备及应用
CN101486997A (zh) 鸡痘病毒rFPV-AIH5/IL2及其构建方法和应用
CN119799747B (zh) 一种基于鱼类神经坏死病毒CP蛋白基因的mRNA、疫苗及其制备方法与应用

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20130121